Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2022.7476
Abstract: Key Points Question Do the demographics, clinicopathologic characteristics, and prognosis differ between breast cancers with no erb-b2 receptor tyrosine kinase 2 (ERBB2; formerly HER2 or HER2/neu) expression (ERBB2 negative) and those with low-level ERBB2 expression… read more here.
Keywords: low breast; breast cancer; clinicopathologic characteristics; erbb2 low ... See more keywords
HER2-low breast cancers: Current insights and future directions.
Sign Up to like & getrecommendations! Published in 2022 at "Seminars in diagnostic pathology"
DOI: 10.1053/j.semdp.2022.07.003
Abstract: In light of the significant clinical benefits of novel HER2-targeting antibody-drug conjugates in advanced HER2-low expressing breast cancers in recent phases I and III clinical trials, particularly trastuzumab-deruxtecan (T-Dxd), the new "HER2-low" category in breast… read more here.
Keywords: low breast; breast; pathology; her2 low ... See more keywords
HER2-Low Breast Cancers.
Sign Up to like & getrecommendations! Published in 2021 at "American journal of clinical pathology"
DOI: 10.1093/ajcp/aqab117
Abstract: OBJECTIVES Recent clinical trials have demonstrated significant clinical benefits from novel therapeutic compounds in breast cancer patient with human epidermal growth factor receptor 2 (HER2) immunohistochemical (IHC) score of 1+ or 2+ and negative in… read more here.
Keywords: low breast; her2 low; breast; breast cancer ... See more keywords
Abstract B47: Silver nanoparticles exhibit subtype specific cytotoxic and therapeutic effects in claudin low breast cancer in vitro and in vivo
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.epso16-b47
Abstract: Triple negative breast cancers (TNBC) are characterized by loss of expression of hormone receptors and decreased expression of the human epidermal growth factor receptor 2 (HER2). TNBC patients do not benefit from current targeted breast… read more here.
Keywords: low breast; breast; clbc; breast cancer ... See more keywords
Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Annals of diagnostic pathology"
DOI: 10.2139/ssrn.4333242
Abstract: BACKGROUND The development of novel human epidermal growth factor receptor 2 (HER2) antibody drug conjugates brings encouraging opportunities for the treatment of HER2-low breast cancer. In this study, we investigated the clinical factors and prognosis… read more here.
Keywords: low breast; her2 zero; her2; breast cancer ... See more keywords
Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14153774
Abstract: Simple Summary HER2-low breast cancer (BC) accounts for more than half of breast cancer patients. Anti-HER2 therapy has been ineffective in HER2-low BC, for which palliative chemotherapy is the main treatment modality. The definitive efficacy… read more here.
Keywords: low breast; her2; breast cancer; her2 low ... See more keywords
HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24098206
Abstract: Despite the great progress made in the understanding of the biological behavior of certain types of invasive breast cancer, there is still no single histological or molecular classification that encompasses such diversity and accurately predicts… read more here.
Keywords: low breast; breast cancer; her2; her2 low ... See more keywords